New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
16:18 EDTBMRNBioMarin reports Q2 adjusted EPS 6c, consensus (42c)
Reports Q2 revenue $191.7M, consensus $158.96M. The increased non-GAAP net income for Q2 compared to the second quarter of 2013 was primarily due to strong uptake of VIMIZIM in its first full quarter of commercial sales, and significant growth in revenues from other commercial products including, Naglazyme, KUVAN, Aldurazyme and Firdapse. VIMIZIM sales topped $14M in first full quarter of sales.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:14 EDTBMRNOptions with decreasing implied volatility
Subscribe for More Information
April 9, 2015
10:48 EDTBMRNDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
April 6, 2015
08:53 EDTBMRNSarepta risk/reward attractive, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use